As cited by the research report titled ‘Global Alpha Emitter Market size study by Type of Radionuclide (Astatine (At-211), Radium (Ra-223), Lead (Pb-212), Bismuth (Bi-212), Actinium (Ac-225), and Other Type of Radionuclides), Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, and Other Medical Applications), Regional Forecasts 2021-2027’, available with MarketStudyReport, global alpha emitter market is projected to expand at 36.7% CAGR and garner significant returns over 2021-2027.
 

Rising awareness regarding the advantages of targeted alpha treatment coupled with increasing number of patients with cardiac and cancer diseases are the major factors driving global alpha emitter market growth. As per the American Cancer Society, around 22,240 women were estimated to be diagnosed with ovarian cancer in 2018, with over 14,070 women dying from the disease in the U.S. 
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4219636/
 

For the record, alpha emitters play an important role in cancer therapies. The properties associated with alpha emitters have led to significant differences between this discipline and other nuclear medicine specialties.
 

Alpha emitters are used in treating malignancies such as ovarian cancer, lymphoma, pancreatic cancer, and melanoma, hence contributing towards the overall market expansion. The treatment method makes use of various radionuclides, including radium, lead, and bismuth.
 

Speaking of negatives, strict regulatory framework and reimbursement issues are likely to hamper the market progression during the projected timespan.
 

Based on type of radionuclide, global alpha emitter industry space is segmented into astatine (At-211), lead (Pb-212), actinium (Ac-225), radium (Ra-223), bismuth (Bi-212), and other type of radionuclides. Considering medical application, the marketplace is divided into prostate cancer, ovarian cancer, endocrine tumors, bone metastasis, pancreatic cancer, and other medical applications.
 

The geographical analysis of the industry includes regions like Asia Pacific, Europe, North America, and Latin America.
 

Asia Pacific is expected to generate notable gains over the estimated timeframe 2021-2027, primarily due to growing number of cardiac and neurological chronic illnesses. For instance, in the United States, 223RaCl2 (Xofigo) is the first alpha emitting radioisotope approved for palliative therapy of prostate cancer bone metastases using indirect physiological targeting.
 

Leading players swaying the worldwide alpha emitter industry trends are Bayer AG, RadioMedix Inc., Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Ltd., IBA Radiopharma Solutions, Actinium Pharmaceuticals Inc., and Alpha Tau Medical Ltd.